Enveloped viruses gain entry into host cells by fusing with cellular membranes, a step required for virus replication. Coronaviruses, including the severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and infectious bronchitis virus (IBV), fuse at the plasma membrane or use receptor-mediated endocytosis and fuse with endosomes depending on the cell or tissue type. The virus Spike (S) protein mediates fusion with the host cell membrane. We have shown previously that an Abl kinase inhibitor, imatinib, significantly reduces SARS-CoV and MERS-CoV viral titers and prevents endosomal entry by HIV SARS S and MERS S pseudotyped virions. SARS-CoV and MERS-CoV are classified as BSL-3 viruses, which can make experimentation into the cellular mechanisms involved in infection more challenging. Here, we use IBV, a BSL-2 virus, as a model for studying the role of Abl kinase activity during coronavirus infection. We found that imatinib and two specific Abl kinase inhibitors, GNF2 and GNF5, reduce IBV titers by blocking the first round of virus infection. Additionally, all three drugs prevented IBV S-induced syncytia formation prior to the hemifusion step. Our results indicate that membrane fusion (both virus-cell and cell-cell) is blocked in the presence of Abl kinase inhibitors. Studying the effects of Abl kinase inhibitors on IBV will be useful in identifying host cell pathways required for coronavirus infection. This will provide insight into possible therapeutic targets to treat infections by current as well as newly emerging coronaviruses.
INTRODUCTION
Coronaviruses are enveloped RNA viruses and include those that cause the common cold as well as the highly pathogenic SARS-CoV and MERS-CoV. In order to gain entry into host cells, all enveloped viruses, including coronaviruses, fuse with cellular membranes.
Coronaviruses bind to cell surface receptors and fuse with the plasma membrane or are endocytosed and fuse with endosomes. This fusion step is required in order for the viral genome to be delivered to the host cell cytoplasm for replication. SARS and MERS coronaviruses fuse with late and early endosomes, respectively, and also at the plasma membrane (1) (2) (3) (4) . The virus S protein mediates fusion between viral and host cell membranes.
Since the outbreaks of SARS-CoV in 2003 and MERS-CoV in 2012, these viruses have been studied extensively in order to understand infection and pathogenicity with the goal of identifying therapeutic targets. A high-throughput screen identified an Abelson (Abl) kinase inhibitor, imatinib, as an inhibitor of SARS-CoV and MERS-CoV (5) . Abl kinases are nonreceptor tyrosine kinases localized to the cytoplasm. Two Abl kinases, Abl1 and Abl2, are expressed in human cells, and are involved in several cellular processes ranging from embryonic morphogenesis to mediating viral infections (6, 7) . Imatinib is a small molecule inhibitor specifically designed to target the Abl kinase portion of the BCR-Abl protein (8) , which results from a chromosomal translocation and causes chronic myeloid leukemia (CML) (9) (10) (11) .
Previously, we have shown that imatinib blocks entry of pseudotyped virions containing SARS-CoV or MERS-CoV S protein (12) . Inhibition of SARS and MERS coronavirus entry by imatinib implicates Abl kinase activity in coronavirus infection, and reports from other groups demonstrate Abl kinase involvement in infections by several other viruses (13) (14) (15) (16) (17) (18) (19) (20) . This strongly suggests the Abl kinase signaling pathway is promising to investigate for development of antiviral therapies.
Based on results from our previous report, we hypothesize that Abl kinase activity is required for entry of other coronaviruses, presumably for virus-cell fusion. The classification of SARS-CoV and MERS-CoV as BSL-3 pathogens and SARS-CoV as a select agent, presents a barrier to the experimental methods that can be performed with the live viruses. Additionally, membrane composition of pseudotyped virions differs from that of true virions since pseudotyped virions bud from the plasma membrane while true virions bud from the endoplasmic reticulum-Golgi intermediate compartment (21, 22) . This could lead to differences in virus-cell fusion and entry mechanisms. Because of this, it is important to evaluate these effects in a live virus system and it is advantageous to find a BSL-2 coronavirus that can be used as a model of infection. Here, we report the effects of imatinib and two other Abl kinase inhibitors, GNF2 and GNF5, on IBV infection. We show that the Abl kinase inhibitors interfere with the first round of IBV infection, indicating an inhibition of virus-cell fusion. In addition, we directly demonstrate that cell-cell fusion and syncytia formation mediated by IBV S is inhibited by imatinib, GNF2 and GNF5 prior to hemifusion, suggesting a role for Abl kinases in both virus-cell and cell-cell fusion events. IBV will be an excellent model to determine the mechanism of Abl kinase action during coronavirus entry in order to find new targets for therapeutic intervention.
MATERIALS AND METHODS

Cells and virus. Vero cells (ATCC CCL-81) were cultured in Dulbecco's Modified Eagle
Medium (DMEM; Invitrogen/Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS; Atlanta Biologicals, Lawrenceville, GA) and 0.1 mg/ml Normocin (InvivoGen, San Diego, CA). Cells were maintained at 37 o C with 5% CO 2 . The wild-type recombinant US Beaudette strain of IBV was used in all experiments (23) .
Plasmids. pCAGGS/SARS-CoV S and pCAGGS/VSV G were previously described (24, 25) .
Two codon optimized plasmids encoding portions of IBV Beaudette S1 and S2 were generously the RRFRR furin cleavage site between S1 and S2) were PCR amplified from a cDNA vector containing codon-optimized sequence of IBV S1, and nucleotides 1614-2955 flanked by HindIII and XmaI sites were PCR amplified from cDNA containing the codon-optimized sequence of IBV S2 (27, 28) . QuikChange mutagenesis (Agilent Genomics) was used to remove the HindIII restriction site between S1 and S2 once the amplicons had been ligated together, and the full coding sequence was confirmed by dideoxy sequencing.
Antibodies and Abl kinase inhibitors. The mouse monoclonal anti-IBV S antibody (9B1B6) recognizes the lumenal domain and was a kind gift from Ellen Collisson (Western University of Health Sciences) (29) . The rabbit polyclonal anti-IBV S antibody to the Cterminus was previously described (26) , as was the rabbit polyclonal antibody to SARS S (anti-SCT) (24) . Rabbit anti-GFP (A-6455) was obtained from ThermoFisher. Alexa Fluor 488 anti- FBS was added to cells -/+ 10 µM imatinib, GNF2 or GNF5 and cells were incubated 18 h at Plaque assay. Vero cells were seeded at 5 x 10 5 per dish in 35 mm dishes 24 h prior to infection. Supernatants from infected cells were serially diluted 10 -1 through 10 -6 in serum-free medium. Cells were washed with serum-free medium, 200 µl of diluted virus was added to each well and adsorption was allowed to proceed for 1 hour at 37 o C with gentle rocking every 10 minutes. 2X DMEM and 1.6% agarose were mixed 1:1 and allowed to cool to 37 o C. Cells were washed with SF medium, and 2 ml DMEM-agarose was added to each well, and cells were incubated for 72 hours at 37 o C. DMEM-agarose was removed from each well, crystal violet staining was used to visualize plaques, and pfu/ml was calculated for each sample.
Fusion Assay. HeLa and Vero cells were plated 3.5x10 5 in 35 mm dishes 24 hr prior to transfection. HeLa cells were transfected as described above with 2 µg pCAGGS-IBV S and 0.5
µg of a plasmid encoding YFP-GPI anchor (Clontech) and Vero cells were transfected with 0.5
µg of a plasmid encoding dsRed (Clontech). Twenty-four h post-transfection, Vero cells were trypsinized and re-plated at 3.5 x 10 5 in 35 mm dishes on coverslips and grown for 1 h in 10 µM imatinib, GNF2 or GNF5 and an equal volume of DMSO. An equal volume of HeLa cells was then added to each well of Vero and DMSO or drug was added to maintain treatment conditions.
Twenty-four h later, cells were placed on ice. On ice, cells were incubated for 20 min in block/perm buffer as described previously (without saponin). A rabbit anti-GFP antibody and mouse anti-IBV S (1:500, 1 h on ice) were used to label surface YFP-GPI and IBV S, respectively. Cells were then fixed for 10 min in 3% PFA at RT, and all following steps were carried out at RT. Cells were washed with PBS and then permeabilized with block/perm buffer (0.05% saponin). Cells were washed and Alexa Fluor 488 anti-rabbit and Cy5 anti-mouse were used for secondary labeling of YPF-GPI and IBV S, respectively. Hoescht 33258 was used to stain DNA. All images were taken within 24 h with the same exposure as described above.
Physical contact between Vero and HeLa cells was defined as an event. Each event was classified either as hemifusion or full fusion. For each treatment condition, total events were normalized to 100% and hemifusion events were normalized to the total number of events.
IBV S processing analysis.
Vero cells were plated 5x10 4 Bands were visualized using the Licor Odyssey CLx and quantified using Image Studio software.
The density of three IBV S bands, corresponding to S0, S2 and S2', was measured and the percent for each band was calculated from the total S for each treatment condition.
RESULTS
IBV titers are reduced in infected Vero cells after treatment with Abl kinase inhibitors
We have shown previously that imatinib lowers SARS-CoV and MERS-CoV titers (12) .
We tested the effects of imatinib, as well as two other Abl kinase inhibitors, GNF2 and GNF5, on IBV infection in order to determine whether IBV could be used as a model to investigate Abl kinase involvement in coronavirus infection. We used two different types of inhibitors in order to determine target specificity as well mechanism of inhibition. Imatinib is a competitive inhibitor that binds near the ATP-binding pocket preventing binding of ATP (31, 32) . Imatinib only binds when the Abl kinase is in the closed, inactive conformation (32) . GNF2 and GNF5
bind to the auto-inhibitory myristate-binding site of the Abl kinase, leading to inactivation of the active kinase by promoting the closed conformation (33) . Imatinib has several cellular targets, while GNF2 and GNF5 specifically inhibit the Abl kinases (33, 34) . Treating infected cells with these specific inhibitors allowed us to evaluate the likelihood of Abl kinase involvement in coronavirus infection as opposed to any of the other cellular targets of imatinib. Vero cells were infected with IBV at MOI 0.1 in the absence and presence of the three inhibitors. Supernatants were harvested 18 h post-infection, and a plaque assay was used to measure viral titers of all samples. Results from this experiment showed that all three drugs significantly decreased virus titer. Imatinib lowered the viral titer ~90% when compared to control, and GNF2 and GNF5 lowered titer ~95% ( Figure 1A ).
Next, we determined whether the decrease in titer was due to reduced virus production in infected cells or the result of fewer cells being infected. Indirect immunofluorescence microscopy using an antibody to the IBV S protein was used to count the number of infected cells in the absence and presence of the Abl kinase inhibitors. Our observations showed that imatinib and GNF5 reduced the number of cells infected by ~90%, and GNF2 decreased the number of infected cells ~80% when compared to control ( Figure 1B) . These results demonstrate that the decrease in IBV titer was due to a decrease in the number of cells infected.
The inhibition by GNF2 and GNF5 suggests Abl1 and/or Abl2 specifically play a role in IBV infection.
Abl kinase inhibitors prevent the first round of IBV infection
Previously, we showed imatinib prevents entry of pseudotyped viruses expressing SARS-CoV or MERS-CoV S protein (12) . In order to determine if IBV is blocked at the entry step by Abl kinase inhibitors, we infected Vero cells at a high MOI and for a duration that would only allow one round of infection. Supernatants were harvested at 8 h post-infection, and IBV titers were measured using a plaque assay. Results from this experiment showed a significant decrease in virus titer when IBV-infected cells were treated with imatinib, GNF2 or GNF5 as compared to control. Titer was reduced ~80% by imatinib and GNF2, and 70% by GNF5 (Figure 2A) . We also observed a decrease in the total number of cells infected by 70% after treatment with all three drugs ( Figure 2B ).
We considered that the decrease in number of cells infected could be due to decreased virus binding to host cell receptors. To address this, we infected Vero cells at a high MOI for 8 h and removed imatinib at indicated time points post-infection ( Figure 3A ). All cells were pre- Because the viral S protein mediates both of these events, it seems likely that virus-cell and cellcell fusion may use the same cellular mechanism. Due to the difficulty in capturing individual virus-cell fusion events, we analyzed cell-cell fusion by measuring syncytium size in the absence and presence of imatinib, GNF2 or GNF5. In Vero cells that were infected with IBV, we observed syncytia formation with an average of 22 nuclei per syncytium ( Figure 4A, B) .
Treatment with imatinib, GNF2 or GNF5 resulted in a statistically significant reduction of nuclei per syncytium. Average syncytium size was reduced to 5, 6 and 4 nuclei for imatinib, GNF2 and GNF5, respectively, an ~95% reduction in the presence of each drug ( Figure 4A, B ).
Next, we determined whether imatinib, GNF2 and GNF5 inhibited syncytia formation induced by the S protein alone when exogenously expressed. Similar to infection, we observed formation of syncytia containing an average of 16 nuclei when Vero cells were transfected with a plasmid encoding IBV S ( Figure 5A, B) . Treating IBV S-transfected cells with Abl kinase inhibitors significantly reduced the number of nuclei per syncytium to ~4 nuclei for imatinib, GNF2 and GNF5, an ~80% reduction ( Figure 5A, B) . Because SARS-CoV is also inhibited by imatinib (12) , we wanted to determine whether Abl kinase inhibitors interfere with fusion induced by SARS-CoV S. To this end, we also tested the effects of all three drugs on syncytia formation produced by the SARS-CoV S protein. Vero cells were transiently transfected with a plasmid encoding SARS-CoV S. The number of nuclei per syncytium was reduced 40% by imatinib, 50% by GNF2 or and 60% by GNF5, as compared to the number of nuclei per syncytium in untreated cells ( Figure 5C, D) . Average syncytium size induced by SARS-CoV S was much smaller than that induced by IBV S (7 nuclei and 16 nuclei per syncytium, respectively), but treatment with all three drugs did reduce the average to three nuclei per syncytium for both IBV S and SARS-CoV S. Note that treatment with Abl kinase inhibitors not only reduced the number of nuclei per syncytium, but also total number of syncytia. We did not quantify this observation, but while more than 50 syncytia containing greater than or equal to three nuclei were found in control cells, we routinely found fewer than 10 syncytia in drugtreated samples. Additionally, there are only two data points for the SARS-CoV S, imatinibtreated cells due to the fact that no syncytia were found in one of the replicate experiments.
Treatment with imatinib, GNF2 or GNF5 had no effect on the total number of cells expressing VSV-G after transfection of a control plasmid (pCAGGS/VSV-G), demonstrating that the effects of these inhibitors were not due to transfection efficiency (data not shown). Together, these results demonstrate that imatinib, GNF2 and GNF5 interfere with syncytia formation mediated by the S protein both during IBV infection and when S protein is exogenously expressed in the absence of infection. The fact that we see the same phenotype with SARS-CoV S and IBV S reinforces the idea that IBV can be used as a model coronavirus to study Abl kinase involvement in coronavirus infection.
Imatinib, GNF2 and GNF5 block IBV S-induced fusion prior to hemifusion
Virus fusion with host cells and virus-induced cell-cell fusion occurs in two steps.
Mixing of the outer membrane leaflets (hemifusion) is followed by inner leaflet mixing and complete fusion. A previous report demonstrated that imatinib inhibits HIV env-induced cellcell fusion at a post-hemifusion step, as indicated by an accumulation of hemifusion events observed in imatinib-treated cells (15) . To determine whether imatinib, GNF2 and GNF5 inhibit IBV S-induced cell-cell fusion pre-or post-hemifusion, we used an assay similar to that used for HIV to distinguish hemifusion from full fusion events. HeLa cells were transfected with one plasmid encoding IBV S and a second encoding YFP targeted to the outer leaflet of the plasma membrane by a glycosylphosphatidylinositol anchor (YFP-GPI). After transfection, these cells were co-cultured with Vero cells transfected with a plasmid expressing soluble dsRed.
Hemifusion between a HeLa and a Vero cell results in both cells containing the GPI anchor at the plasma membrane, with cytoplasmic dsRed signal observed in only one of the two cells. Full cell-cell fusion results in both cells with cytoplasmic dsRed signal and containing the labeled GPI anchor at the plasma membrane. Fusion events were observed and categorized as full fusion or hemifusion ( Figure 6A ). IBV S staining is not shown, but was used to ensure coexpression of IBV S and YFP-GPI in HeLa cells. We observed 54 total fusion events in the control sample and 25, 20 and 24 total fusion events in samples treated wtih imatinib, GNF2 and GNF5 samples, respectively. Hemifusion events accounted for 14% of all fusion events from control cells, and 8%, 11% and 12%, in cells treated with imatinib, GNF2 or GNF5, respectively ( Figure 6B ).
Although total fusion events in drug-treated cells were reduced as expected, treatment with imatinib, GNF2 or GNF5 showed no significant change in the percent of hemifusion events as compared to control cells ( Figure 6B ), suggesting that Abl kinase inhibitors block the initial hemifusion step. This result demonstrates that Abl kinase inhibitors interfere with the cell-cell fusion necessary for syncytia formation, and provides evidence that these drugs may inhibit virus-cell fusion by preventing hemifusion, the first step in membrane mixing.
Abl kinase inhibitors do not affect IBV S processing
We considered that treatment with Abl kinase inhibitors could affect IBV S processing and that this could be the cause of the block in cell-cell fusion. The full length S protein (S0) undergoes two cleavage events necessary for cell-cell fusion to take place. The first occurs at the S1/S2 site and produces two fragments, S1 and S2 (2) . The second cleavage occurs at the S2' site, resulting in exposure of the fusion peptide (3, 4) . In the strain of Vero cells used here, IBV S is cleaved during virion exocytosis, providing a fusion-competent virus prior to host cell receptor binding. Because exposure of the fusion peptide has been shown to be necessary for cell-cell fusion and syncytia formation, we measured the amounts of each cleavage product after treatment with imatinib, GNF2 or GNF5. None of the drug treatments decreased the relative amounts of S0, S2 or S2' (Figure 7A, 7B) , indicating that IBV S protein processing and cleavage are not affected by Abl kinase inhibitors.
DISCUSSION
We have demonstrated here that the Abl kinase inhibitors, imatinib, GNF2 and GNF5
reduce the viral titer of IBV by decreasing the number of cells infected, and that the first round of virus infection is inhibited. Our data show that each of the three inhibitors prevents syncytia formation induced by IBV as indicated by fewer nuclei per syncytium as compared to infected, untreated cells. A decrease in nuclei per syncytium in IBV S-and SARS-CoV S-expressing cells treated with imatinib, GNF2 or GNF5 demonstrates Abl kinase inhibitors prevent syncytia formation induced by the S protein in the absence of other viral proteins. Our results demonstrate that fusion was inhibited before the hemifusion step, prior to any lipid mixing of membranes. Additionally, we show that cleavage of S into S2 and S2' was not affected by imatinib, GNF2 or GNF5, suggesting that IBV S processing and cleavage is independent of Abl kinase activity. The inhibition by specific inhibitors of Abl kinases, GNF2 and GNF5, strongly suggests that IBV infection requires the activity of Abl1 and/or Abl2. Our previous report showed that Abl2, but not Abl1, is required for entry of SARS-CoV and MERS-CoV (37) . They are involved in T cell signaling (38, 39) , embryonic development and (6, 40) , and cell migration and invasion in cancer (41, 42) . The distinct domains provide Abl kinases with the ability to act as scaffolds to facilitate building of signaling complexes (6, 43, 44) , and to regulate protein function through phosphorylation of downstream protein targets (43) . Binding actin through the FABD directly regulates cytoskeleton dynamics (44) (45) (46) (47) to activate the essential cellular pathways described above. We hypothesize that coronavirus infection requires the multi-functional actions of Abl kinases for virus fusion at the plasma membrane or endosome membrane in order to gain entry into host cells.
It is likely that virus-cell and cell-cell fusion induced by the coronavirus S protein use the same or a very similar mechanism. Because Abl kinase activity plays a role in cytoskeletal rearrangement (47, 48) , we hypothesize that Abl kinase inhibitors act by interfering with actin dynamics required for virus-cell and cell-cell fusion. Our hypothesis is supported on two fronts.
First, cytoskeletal dynamics have been implicated in infection by several viruses (13) (14) (15) (16) (17) (18) (19) (20) . Actin cytoskeleton rearrangement was shown to be required for infection by Coxsackievirus (13),
Vaccinia virus (14), HIV (15, 16) , and Variola and monkeypox (17) . These studies demonstrate that cytoskeletal rearrangement is a common mechanism required by many cellular processes that can be hijacked by viruses during infection, as reviewed by others (7, (49) (50) (51) . Second, Abl kinase's role in actin cytoskeletal rearrangement is required for essential cell-cell fusion events, including but not limited to, osteoclast (52) and myoblast fusion (53, 54) during development.
Actin-induced podosome like structures are required for fusion of osteoclasts and myoblasts, presumably to alter membrane tension (55, 56) . Interestingly, Harmon et al. (15) reported that cell-cell fusion mediated by the HIV envelope protein was inhibited by imatinib at a posthemifusion step. We did not observe an increase in hemifusion events after treatment of IBVinfected cells with imatinib, GNF2 or GNF5. Since we used a different virus, cell line and fusion assay, it is difficult to compare the two results. We favor the idea that virus interaction with host cell receptors induces actin rearrangements through Abl kinase activity, and that this brings cell membranes in close proximity to allow hemifusion followed by full fusion (55) .
Our results demonstrate that the coronavirus-membrane fusion step is blocked by Abl kinase inhibitors, as suggested by our previous report (12) . Our results also indicate that Abl kinase activity may be involved in the membrane fusion events required for infection by all coronaviruses, and that imatinib, GNF2 and GNF5 have the potential to be general coronavirus inhibitors. This work strongly suggests that proteins involved in the Abl kinase pathway are excellent targets for developing treatments for coronavirus infections. Current studies are underway to determine the Abl kinase functions involved in coronavirus infection as well as determining whether the activity of Abl1 or Abl2, or both kinases is required for coronavirus infection. Given the role Abl kinases play in infection by so many other viruses makes this pathway a prime target for use in developing broadly acting antiviral therapeutics. 
